Records containing: Schizophrenia

This is the wording recorded or indexed by the source. An agency index term is not necessarily an authorised indication. Co-listed drug names are not linked to this term as a treatment relationship.

• CLINICAL_TRIALS study record update · 2011-06-08
  A Multi-center, Inpatient and Ambulatory, Phase 2, Double Blind, Randomized, Placebo-controlled Proof of Concept Study of CYR-101 in Patients With DSM-IV Schizophrenia
• CLINICAL_TRIALS study record update · 2011-06-08
  Randomized, Double-blind, Placebo- and Active-controlled Parallel Group, Dose-response Study to Evaluate the Efficacy and Safety of 3 Fixed Dosages of Paliperidone Extended Release (6, 9, and 12 mg/Day) and Olanzapine (10 mg/Day) With Open-label Extension in Treatment of Schizophrenia
• CLINICAL_TRIALS study record update · 2011-06-08
  Randomized, Multi-center, Open Label Trial Comparing Risperidone Depot (Microspheres) and Olanzapine Tablets in Patients With Schizophrenia or Schizoaffective Disorder
• CLINICAL_TRIALS study record update · 2011-06-08
  A Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Dose Study to Evaluate and Compare the Pharmacokinetics of ER OROS Paliperidone in Healthy Japanese and Caucasian Subjects.
• CLINICAL_TRIALS study record update · 2011-06-08
  Open-label Study to Evaluate the Safety and Pharmacokinetics of Single- and Multiple-dose Extended-release OROS Paliperidone in Pediatric Subjects (=10 to =17 Years of Age) With Schizophrenia, Schizoaffective Disorder, or Schizophreniform Disorder
• Organize your saved records without ads with Plus.
• CLINICAL_TRIALS study record update · 2011-06-08
  A Comparative Evaluation of the Pharmacokinetics and Pharmacodynamics Under Fasting and Fed Conditions of 2 Paliperidone Extended-release Formulations With Paliperidone Oral Solution in Healthy Adults
• CLINICAL_TRIALS study record update · 2011-06-08
  Pharmacokinetics of Paliperidone in Subjects With Moderate Hepatic Impairment as Compared to Subjects With Normal Hepatic Function.
• CLINICAL_TRIALS study record update · 2011-06-08
  Open Label Extension to R076477-SCH-305 to Evaluate the Safety and Tolerability of Paliperidone ER in Subjects With Schizophrenia.
• CLINICAL_TRIALS study record update · 2011-06-08
  A Randomized, Double-Blind, Placebo-Controlled Clinical Study of the Efficacy and Safety of Risperidone for the Treatment of Schizophrenia in Adolescents
• CLINICAL_TRIALS study record update · 2011-06-08
  A Randomized, Crossover Study to Evaluate the Overall Safety and Tolerability of Paliperidone Palmitate Injected in the Deltoid or Gluteus Muscle in Patients With Schizophrenia
• CLINICAL_TRIALS study record update · 2011-06-08
  The Efficacy and Safety of Risperidone in Adolescents With Schizophrenia: a Comparison of Two Dose Ranges of Risperidone
• CLINICAL_TRIALS study record update · 2011-06-08
  Pivotal Bioequivalence Study With 15 mg ER OROS Paliperidone Comparing the Phase 3 Formulation With the To-be-marketed Formulation and Evaluation of Food Effect on the to be Marketed Formulation in Healthy Male Subjects
• CLINICAL_TRIALS study record update · 2011-06-08
  A Randomized, DB, PC and AC, Parallel Group, Dose-Response Study to Evaluate the Efficacy and Safety of 3 Fixed Dosages of Extended Release OROS� Paliperidone (6, 9, 12 mg/Day) and Olanzapine (10 mg/Day), With Open-Label Extension, in the Treatment of Subjects With Schizophrenia - Open Label Phase
• CLINICAL_TRIALS study record update · 2011-06-08
  A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Response Study to Evaluate the Efficacy and Safety of 3 Fixed Doses (50 mg eq., 100 mg eq., and 150 mg eq.) of Paliperidone Palmitate in Subjects With Schizophrenia
• CLINICAL_TRIALS study record update · 2011-06-08
  A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-response Study to Evaluate the Efficacy and Safety of 3 Fixed Doses (25 mg eq, 50 mg eq, and 100 mg eq) of Paliperidone Palmitate in Patients With Schizophrenia
• CLINICAL_TRIALS study record update · 2011-05-24
  A Study of Galantamine HBr as an Adjunctive Treatment to Atypical Antipsychotic Medications in Outpatients With Schizophrenia and Associated Cognitive Deficits.
• CLINICAL_TRIALS study record update · 2011-05-24
  A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of 50 and 100 Mg-eq of Paliperidone Palmitate in Patients With Schizophrenia
• CLINICAL_TRIALS study record update · 2011-05-24
  Dose-proportionality Study of the Five ER OROS Paliperidone To-be-marketed Tablet Strengths (3, 6, 9, 12, and 15 mg) in Healthy Male Subjects
• CLINICAL_TRIALS study record update · 2011-05-20
  Expanding Rapid Ascertainment Networks of Schizophrenia Families in Taiwan
• CLINICAL_TRIALS study record update · 2011-05-19
  Study ADH.E.R.E.: "Therapeutic ADHerence and Treatment Strategies: Mental Health Registry"
• CLINICAL_TRIALS study record update · 2011-05-19
  A Randomized, Open-label, Single-center, Crossover Study of the Potential Effects of Paroxetine on the Pharmacokinetics of a Single Dose of Paliperidone Extended-release in Healthy Men
• CLINICAL_TRIALS study record update · 2011-05-19
  Aggressiveness and Agitation of Acute Psychotic Patients: Influence in Safety and Effectiveness of Risperidone Treatment
• CLINICAL_TRIALS study record update · 2011-05-19
  Study PROFILe3: Clinic Observations Profile of Relapse and Readmission in Emergency/Acute Settings: Epidemiologic Survey in Schizophrenic Patients
• CLINICAL_TRIALS study record update · 2011-05-19
  BMI-2002 Study: Evaluation of Functionality and Evolution of Body Weight of Psychotic Patients With a High Body Mass Index
• CLINICAL_TRIALS study record update · 2011-05-19
  A Randomized, Open-Label, Dose-Blinded, Multicenter, 6-Month Study of Safety and Tolerability of 3 Dose Levels of SM-13496 (Lurasidone) in Patients With Schizophrenia